Claimed effect · CagriSema

Does CagriSema help with body weight?

A
Grade A — established in humans1 phase 3 RCT (n=3,417, 68 wk) · effect size: large
Short answerEstablished in humans. 1 phase 3 RCT (n=3,417, 68 wk) point the same way: a large effect. REDEFINE 1 randomised 2,108 people to the combination, 302 to semaglutide alone, 302 to cagrilintide alone and 705 to placebo. The combination lost 20.4% against 3.0% on placebo; the single agents landed in between. Published in the New England Journal of Medicine.

What the studies show

REDEFINE 1 randomised 2,108 people to the combination, 302 to semaglutide alone, 302 to cagrilintide alone and 705 to placebo. The combination lost 20.4% against 3.0% on placebo; the single agents landed in between. Published in the New England Journal of Medicine.

“The estimated mean percent change in body weight from baseline to week 68 was -20.4% with cagrilintide-semaglutide as compared with -3.0% with placebo (estimated difference, -17.3 percentage points; 95% confidence interval, -18.1 to -16.6; P<0.001).”

Verbatim, from the abstractGarvey WT, et al. Coadministered cagrilintide and semaglutide in adults with overweight or obesity (REDEFINE 1). N Engl J Med, 2025

Several well-run randomised trials in people, pointing the same way. You can plan around this. It still says nothing about whether the effect is worth the side effects for you.

  1. 1

In context

CagriSema is a once-weekly co-injection of cagrilintide, an amylin analogue, with semaglutide 2.4 mg. In REDEFINE 1, a 3,417-person phase 3 trial published in 2025, it produced 20.4% average weight loss at 68 weeks against 3.0% on placebo; in people with type 2 diabetes the figure was 13.7%. Both trials are peer-reviewed. It is not yet approved anywhere, and anything sold under the name is not the trial product.

CagriSema is investigational (filed). Legal status differs by country — see the regulation section or the jurisdiction pages.

Questions

Is CagriSema proven to help with body weight?
Yes, as far as human trials can show it: 1 phase 3 RCT (n=3,417, 68 wk). LYO grades this outcome A.
What studies are behind the grade?
REDEFINE 1 randomised 2,108 people to the combination, 302 to semaglutide alone, 302 to cagrilintide alone and 705 to placebo. The combination lost 20.4% against 3.0% on placebo; the single agents landed in between. Published in the New England Journal of Medicine.
Is CagriSema approved for this?
No. CagriSema is investigational (filed); it is not an approved medicine for any indication in the jurisdictions LYO covers.

Other outcomes for CagriSema

Written and maintained by LYO Research — how pages are written and checked. Reviewed 7 October 2026. Grades count human evidence only; see how LYO grades. Not medical advice. Correct this page →